Merck is expanding its pipeline and portfolio of cardio-pulmonary disease treatments by acquiring Verona Pharma plc. The Rahway pharma giant announced the deal for the biopharmaceutical company ...

Efforts to innovate in the fight against influenza include universal influenza vaccines — none successful so far. Merck is aiming for universality with a drug, not a vaccine, via the $9.2 billion ...

Photo screenshot: stockexplorers YOUTUBE/ Cidara Therapeutics ($CDTX): Why Wall Street is Tripling Price Targets on this Small Biotech Stock The pharmaceutical giant ...

Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn), after receiving regulatory approvals and fulfilling customary ...

Acquisition strengthens Merck’s cardio-pulmonary portfolio with addition of Ohtuvayre® (ensifentrine), a first-in-class COPD maintenance treatment, that is expected to grow into the next decade Merck ...

Merck plans to acquire Cidara Therapeutics Inc. in a deal worth $9.2 billion. As part of a deal announced Nov. 14, the Rahway-based drugmaker will gain access to the San Diego-headquartered biotech’s ...

Merck said on Monday it would split its business into two, creating ⁠a division for its cancer franchise while grouping its ​non-oncology treatments separately.

CD388 is an investigational long-acting, strain-agnostic antiviral agent currently in Phase 3, designed to prevent influenza infection in individuals at higher risk of influenza complications ...

Merck's newest acquisition could help it launch a promising flu candidate. Several other ongoing developments are helping paint a bright post-Keytruda picture. Merck is also an excellent dividend ...

The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. increasingly looks to life after its oncology megablockbuster, the company is honing its focus on new and upcoming ...

(RTTNews) - Merck (MRK) and Cidara Therapeutics, Inc. (CDTX) have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Cidara for $221.50 per share in cash, for a ...

Merck spent a small fortune on the acquisition of Acceleron Pharma, and so far, it's paying off. Recent phase 2 data suggests the pharmaceutical giant could get even more bang for its buck. Despite ...